Existing backer SoftBank China was among the participants in a series E round that will support the expansion of Taimei Technology's clinical trial management platform.
China-based pharmaceutical software developer Taimei Technology has collected $80m in a series E round featuring SoftBank China, a local subsidiary of telecommunications group SoftBank, China Money Network reported yesterday.
The round, disclosed at Taimei’s annual meeting late last week, was led by hedge fund manager Tiger Global Management and included venture capital firm Cowin Venture.
Founded in 2013, Taimei has developed software that can manage the implementation of clinical drug trials, bringing together drug developers, patients, researchers, regulators, research institutes,…
